A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Summary

This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed ≥2 prior lines of standard treatment will be recruited. The purpose of this trial is to evaluate the efficacy, safety, pharmacokinetic (PK) and immunogenicity characteristics of TRS005 via intravenous drip.

Timeline

Start

2025-09

Primary completion

2027-01

Completion

2027-09

Drugs

Indications